Allergy immunotherapies market to rise by 9.62% CAGR to $1.2b until 2028

SCIT and SLIT treatments are gaining traction in managing reactions and illnesses.

The global market for allergy immunotherapies is projected to grow by approximately $1.2b until 2028 at a compound annual growth rate (CAGR) of 9.62%, according to Technavio.

The report revealed that the market is driven by a rising prevalence of allergies worldwide.

Moreover, advancements in technology and a growing awareness and acceptance of treatments have also driven the market’s expansion.

By product segment, subcutaneous immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT) treatments are increasingly being adopted to manage allergic reactions and illnesses.

However, the report noted high costs and limited insurance coverage could impact market growth, limiting patient access to certain therapies.

Meanwhile, complex administration procedures serve as an additional market challenge, with allergens such as pollen varying by region and season, affecting treatment planning and delivery.

“Overall, addressing these challenges requires innovative solutions, improved patient education, and collaborative efforts between healthcare providers and industry stakeholders,” Technavio said.